Abstract: The invention provides an electronic device, a PCB and an electric tool; the electronic device comprises a main body, a first electric connecting part, a variable resistor, a speed regulating contact, a reversing electric connecting part, a reversing contact, a speed regulating handle and a reversing handle, the first electric connecting part is connected with the main body in a melt adhesive curing mode, and one end of the first electric connecting part is exposed out of the main body; the speed regulating handle and the main body form a first space, the speed regulating contact and the variable resistor are arranged in the first space, and under the drive of the speed regulating handle, the speed regulating contact and the variable resistor relatively slide; under the driving of the reversing handle, the reversing contact and the reversing electric connecting part relatively slide for reversing.

Abstract: Embodiments of the disclosure provides a pico-base station configuration method and apparatus, a storage medium and an electronic apparatus, and relate to the technical field of wireless network pico-base station technology.

Abstract: The present disclosure provides a metal wire and a method for manufacturing the same. The method for manufacturing the metal wire includes: forming a metal bar on a substrate; forming a mask above the metal bar, a width of the mask being smaller than a width of the metal bar, and an orthographic projection of the mask on the substrate is within an orthographic projection of the metal bar on the substrate; and wet etching the metal bar to a saturation state under a protection of the mask to form a metal wire, a width of the metal wire being smaller than the width of the mask. The above method can form the metal wire with a high thickness and a narrow line width.

Abstract: A mounting bracket includes a bracket body, a locking assembly and support foot. The bracket body is configured for component installation. The locking assembly is arranged on the bracket body, and the support foot is arranged on the bracket body. The support foot is slide along the up and down direction of the bracket body, and the locking assembly is configured to lock the support foot at a preset position. Through the above structure, the support foot is installed on the ground and used to support the bracket body, and the locking assembly locks the support foot at a preset position to correspondingly adjust the height of the bracket body from the ground, so as to adjust the suspension height of the components installed on the bracket body.

Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.

Abstract: The application discloses a method, apparatus and system for scanning an animal. The method includes obtaining a species of an animal to be scanned, identifying a type of an animal cabin where the animal to be scanned is located, and determining whether the species of the animal to be scanned matches the type of the animal cabin, determining and presenting a corresponding scanning protocol that matches the species of the animal to be scanned if the species of the animal to be scanned matches the type of the animal cabin, and perform a scan according to the corresponding scanning protocol, or according to a user-defined scanning protocol.

Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.

Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.

Abstract: In certain embodiments, the present disclosure provides methods comprising contacting a cell with a compound comprising a modified oligonucleotide complementary to a nucleic acid transcript. In certain such embodiments, the modified oligonucleotide does not interact or interacts poorly with a mRNP complex or granule. In certain such embodiments the modifications and/or motifs of the modified oligonucleotide do not promote interaction with a mRNP complex or granule. In certain embodiments, the present disclosure provides methods comprising contacting a cell with a compound comprising a modified oligonucleotide thereby reducing the size or amount of protein aggregation in the cell. In certain such embodiments, the protein aggregate is a mRNP granule. In certain such embodiments, the modifications and/or motifs of the modified oligonucleotide promote interaction with a protein aggregate, such as a mRNP granule, that results in disruption of the protein aggregate.

Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.

Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.

Abstract: The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having one or more chirally enriched phosphorothioate intemucleoside linkages. In certain embodiments, the modified oligonucleotide decreases expression of target mRNA.

Abstract: The present disclosure provides oligomeric compounds comprising a modified oligonucleotide that induces no-go decay of a target mRNA. In certain embodiments, the modified oligonucleotide is complementary to a region within the 3? half of the coding region of the target mRNA.

Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.

Abstract: In certain embodiments, the present disclosure provides compounds and methods of increasing the amount or activity of a target protein in a cell. In certain embodiments, the compounds comprise a translation suppression element inhibitor. In certain embodiments, the translation suppression element inhibitor is a uORF inhibitor. In certain embodiments, the uORF inhibitor is an antisense compound.

Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.

Abstract: Disclosed herein are methods for increasing antisense activity by modulating translation. In certain embodiments, a compound comprising an antisense oligonucleotide is co-administered with an inhibitor of translation.

Abstract: The present invention provides N-acetyl-muramic acid (NAM) derivatives having Formula I, wherein Xa is selected from the group consisting of X1-X59, Ya is selected from the group consisting of H, monophosphate, uridine diphosphate and ethyl azide linker prepared from 2-azido-ethanol, and Za is selected from the group consisting of OH, an ethylene diamine coupled fluorophore, a peptide and a peptide with an ethylene diamine coupled fluorophore, wherein the peptide is selected from the group consisting of a monopeptide, a dipeptide, a tripeptide and a pentapeptide. Also provided are methods for synthesizing NAM derivatives and methods for modulating Nod2 in cells, modifying bacterial cell wall or modulating innate immune response by a subject to bacterial cells upon exposure to NAM derivatives.

Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.

Abstract: A polytetrafluoroethylene textile and manufacturing method thereof is disclosed. a pretreatment process is performed on a plurality of polytetrafluoroethylene yarns. In the pretreatment process, a step of extending the polytetrafluoroethylene yarns are extended, the polytetrafluoroethylene yarns are knitted into a polytetrafluoroethylene fabric, the shape of the polytetrafluoroethylene fabric is fixed, and the polytetrafluoroethylene fabric are de-knitted into the polytetrafluoroethylene yarns with a plurality of knit-assisting parts. A second knitting process is performed to knit the polytetrafluoroethylene yarns and a plurality of artificial yarns together to obtain the polytetrafluoroethylene textile.